Clinical trials - Press Releases

Date	Title	Company
25-Aug-2021	Almac Group and PILA PHARMA Ink Manufacturing Agreement	Almac
24-Aug-2021	LEXICON'S SOTAGLIFLOZIN DEMONSTRATES ADDITIONAL COMPELLING BENEFITS IN REDUCING CARDIOVASCULAR ENDPOINTS: RESULTS FROM SOLOIST AND SCORED TRIALS	Lexicon Pharmaceuticals, Inc.
24-Aug-2021	Bavarian Nordic Initiates Phase 2 Clinical Trial of COVID-19 Booster Vaccine	Bavarian Nordic A/S
24-Aug-2021	Nouscom announces first patient dosed in a Phase 1b Trial with NOUS-PEV, a novel personalized cancer immunotherapy, in advanced melanoma or lung cancer	Nouscom
23-Aug-2021	Targeting the Putamen with Gene Therapy Leads to Sustained Improvements in Motor and Non-Motor Functions in Children with AADC Deficiency	PTC Therapeutics, Inc.
22-Aug-2021	Anatara’s IBS-D clinical trial to leverage Microba Life Sciences’ precision microbiome analysis	Microba Life Sciences
20-Aug-2021	Almac Group and PILA PHARMA Ink Manufacturing Agreement	Almac
20-Aug-2021	Clinerion patent for technology underpinning Patient Network Explorer is published.	Clinerion Ltd.
19-Aug-2021	New England Journal of Medicine Publishes 12-Week Results from Study Evaluating Atogepant for the Preventive Treatment of Migraine	AbbVie
18-Aug-2021	Cidara Therapeutics and Mundipharma Announce Completion of Enrollment in the Phase 3 ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis	Cidara Therapeutics
18-Aug-2021	Tiziana Announces Publication of a Peer Reviewed Article on Data from the Clinical Trial with Intranasally Administered Foralumab, Its Proprietary Fully Human Anti-CD3 Monoclonal Antibody, in Mild to Moderate COVID-19 Patients in Brazil	Tiziana Life Sciences plc
17-Aug-2021	Cidara Therapeutics and Mundipharma Announce Completion of Enrollment in the Phase 3 ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis	Mundipharma
17-Aug-2021	Moderna Announces First Patient Dosed in Phase 1/2 Study of mRNA-3705 for Methylmalonic Acidemia	Moderna
17-Aug-2021	Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study	GSK
16-Aug-2021	Lilly's lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic dermatitis in two Phase 3 trials	Lilly
16-Aug-2021	Lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic dermatitis in two Phase 3 trials	Almirall S.A.
12-Aug-2021	iTeos Reports Second Quarter 2021 Financial Results and Provides Business Update	iTeos Therapeutics, Inc.
11-Aug-2021	PONVORY®▼ (ponesimod), a Once Daily, Oral Therapy Authorised in Great Britain for the Treatment of Adults with Relapsing Forms of Multiple Sclerosis (RMS) with Active Disease Defined by Clinical or Imaging Features	Janssen
11-Aug-2021	Precision for Medicine and Trialbee Partner to Advance Clinical Trials for Complex Therapies and Speed Shift Toward Precision Medicine	Precision for Medicine
09-Aug-2021	SCOTTISH MEDICINES CONSORTIUM (SMC) ACCEPTS TREMFYA®▼ (GUSELKUMAB), THE FIRST IL-23 p19 INHIBITOR TREATMENT, FOR ACTIVE PSORIATIC ARTHRITIS (PsA)	Janssen